ISSN- 2230-7346
Journal of Global Trends in Pharmaceutical Sciences

THE SILENT SHIFT: UNDERSTANDING HORMONAL CHANGES IN AGING MEN

Asiya Shaik*, V. Ragha Sai Pravallika, Velkuru Mohith, Uppari Nayomi, Tippani Tejaswi, Vangapalli Akshitha

Malla Reddy College of Pharmacy, Maisammaguda, Secunderabad, Hyderabad, 500100, Medchal District, Telangana, India

*Corresponding author E-mail: asiyashaik99999@gmail.com

ARTICLE INFO

Key words:
Late-Onset Hypogonadism, Ageing Male, Andropause

Access this article online
Website: https://www.jgtps.com/
Quick Response Code:

ABSTRACT

The term *male menopause* was first introduced in 1944 to describe a constellation of age-related complaints in men that bore partial resemblance to the climacteric symptoms experienced by women during menopause. Over subsequent decades, continuous research has contributed to a more nuanced understanding of these symptoms, leading to the recognition of a distinct clinical and biochemical entity now commonly referred to as *Late-Onset Hypogonadism (LOH)* or *andropause*. The pathophysiological mechanisms underlying LOH are multifactorial. Key contributing factors include the natural aging of the gonads; elevated levels of sex hormone-binding globulin (SHBG); increased activity of visceral adipose tissue; and reduced sensitivity of androgen receptors. A particularly contentious issue remains the role of testosterone replacement therapy (TRT) in the treatment of LOH. This review critically examines the historical context, evolving diagnostic framework, underlying pathophysiology, and current perspectives on the risks and benefits of testosterone therapy.

INTRODUCTION

Andropause is a condition marked by a gradual decline in testosterone levels in aging men, often leading to reduced sexual satisfaction and a general decrease in physical and emotional well-being. The term is derived from the Greek words *"andras"* (man) and *"pause"* (cessation), symbolizing a slowdown in male hormonal activity. Common symptoms—collectively referred to as the male climacteric—include hot flashes, fatigue, anxiety, decreased libido, irritability, and depression. Over time, various terms have been used to describe this condition, such as male menopause, male climacteric, aging male syndrome, ADAM (Androgen Decline in the Aging Male), and Late-Onset Hypogonadism (LOH). The concept was first introduced in 1944 by Heller and Myers, who Identified a pattern of declining sexual and overall health in older men and associated it with reduced testosterone levels, coining the term "male menopause[1]". The Vermeulen group suggests that the only distinction in "climacteric symptoms" between men and women lies in their incidence rates. Heinemann and Saad further argue that there is no significant gender difference when it comes to symptoms like rapid and excessive sweating. These findings have contributed to the use of the term "male menopause," or *andropause*. Despite ongoing research, emotional issues associated with low testosterone are often misdiagnosed as bipolar disorder or depression, and society continues to overlook the impact of these issues on men's well-being [2-4]. True andropause is

defined as a condition experienced by men who have lost the ability to testify due to illnesses, injuries, or advanced prostate cancer, particularly those who have undergone surgical or medicinal castration. As men age, their testosterone levels decrease by approximately 1% annually. This decline is most noticeable in free testosterone levels, largely due to changes in the SHBG protein. However, the rate of testosterone decline varies among individuals, influenced by factors such as medication use, obesity, and chronic illnesses. By managing health and lifestyle factors, this decline can be slowed down[5-6]. Signs of aging in men often reflect symptoms similar to those experienced by women during menopause. The concept of male aging and its effects on general health and sexual function was first recognized in 1944 by Hellers and Meyers. They noted that as men age, they often experience a decline in physical and sexual health, which they attributed to a decrease in testosterone levels[7]. This led to the introduction of the term ‘‘male menopause,’’ referring to a phase in a man's life when symptoms resembling those of female menopause occur due to hormonal changes, particularly the decline in testosterone. Heinemann and Saad further explored this idea, noting that certain symptoms, such as sudden and excessive sweating, are not exclusive to women. These symptoms are, in fact, common to both genders and are associated with hormonal fluctuations that occur with age[8]. The Vermeulen group, in their research, expanded on this notion, arguing that "climacteric symptoms"—a term used to describe the physical and emotional changes linked to hormonal decline—affect both men and women. They emphasized that while the symptoms may be similar, the incidence rates differ between the sexes, with women experiencing them more frequently during menopause, while men may encounter them to a lesser extent but still experience a range of symptoms related to aging[9]. This recognition of shared climacteric symptoms highlights the complex and often overlooked process of aging in men, which has parallels to the female menopausal experience. For men, these symptoms might include fatigue, depression, decreased libido, changes in body composition, and even mood swings, all of which are commonly linked to reduced testosterone levels[10]. These findings supported the use of the term "male menopause," or "andropause." However, despite considerable time and research, emotional disorders associated with decreased androgen levels are frequently misdiagnosed as symptoms of depression or bipolar disorder. As a result, there is still a lack of widespread social awareness regarding the potential impact on men's well-being as they age[11]. Current studies indicate that there are no well-defined, age-specific reference ranges for testosterone. Most existing guidelines use a threshold of 10 nmol/L as the lower limit. Previously, testosterone therapy was sometimes considered for men with symptoms of deficiency, even if their testosterone levels were within the normal range, based on the belief that significant individual variation might mask a personal decline. However, this approach is no longer supported in the era of evidence-based medicine[12]. In 2002, the International Society for the Study of the Ageing Male (ISSAM) released its first guidelines for diagnosing and treating late-onset hypogonadism (LOH), which were later updated in 2005 and 2008. These guidelines state that a diagnosis of LOH should only be made when clinical symptoms are accompanied by confirmed low testosterone levels. They reject the practice of initiating treatment based solely on positive results from symptom questionnaires[13]. A large, recent study published in the *New England Journal of Medicine* offers new insights into androgen deficiency. The European Male Ageing Study (EMAS), a multi-center study, involved 3,369 men aged 40 to 79 years (average age 59.7), who underwent thorough health evaluations. These included questionnaires, physical and cognitive performance tests, and blood analyses for hormonal and biochemical markers. From an initial list of 32 symptoms drawn from the EMAS questionnaires, researchers identified only nine that were significantly associated with low total or free testosterone levels [14].

These symptoms effectively differentiated between symptomatic and asymptomatic men. The key symptoms linked to low testosterone were: Sexual symptoms: reduced frequency of morning erections decreased sexual thoughts, and erectile dysfunction.

Physical symptoms: difficulty engaging in vigorous physical activity (e.g., running, lifting heavy objects), difficulty walking more than 1 km, and difficulty bending, kneeling, or stooping.

Psychological symptoms: low energy, feelings of sadness or "downheartedness," and fatigue.

However, among these, only the three sexual symptoms showed a true syndromic association with low testosterone levels. The study found a clear inverse relationship—the more sexual symptoms present, the lower the testosterone level. Other symptoms, such as altered sleep patterns, poor concentration, feelings of worthlessness, nervousness, anxiety, or trouble rising from a chair, were not linked to testosterone deficiency and were ruled out as indicators of male menopause.

The data also helped define hormonal thresholds at which symptoms become more likely. An increased probability of experiencing the three sexual symptoms and reduced physical function was observed when: Total testosterone was between 8.0–13.0 nmol/L (2.3–3.7 ng/mL) Free testosterone was between 160–280 pmol/L (46–81 pg/mL) Ultimately, the study concluded that late-onset hypogonadism (LOH), when strictly defined as the presence of at least three sexual symptoms combined with a total testosterone level below 11 nmol/L (3.2 ng/mL) and a free testosterone level below 220 pmol/L (64 pg/mL), affects only about 2% of men [12,15]. The study by Turnover highlighted that while andropause and menopause may share some similar clinical symptoms, they differ significantly in the nature of hormonal changes. In men, the decline in testosterone—the primary male sex hormone—is gradual and permanent, not sudden or transient as seen in menopause. On average, testosterone levels decrease by about 1% per year. A more recent study by Belchetz et al. estimated this decline at approximately 1.4% annually [16]. Historically, the diagnosis of andropause has relied largely on clinical symptoms assessed through various questionnaires, which capture patients' subjective experiences [17]. Wu et al. examined the prevalence of these symptoms and found the following rates among men diagnosed with andropause:

- Low libido – 91%
- Lack of energy – 89%
- Erectile dysfunction – 79%
- Drowsiness after meals – 77%
- Memory decline – 77%
- Loss of pubic hair – 70%
- Sadness and irritability – 68%
- Reduced physical endurance – 66%
- Loss of facial hair – 55%
- Difficulties at work – 51%

Two questionnaires have become the most widely used tools for assessing the severity of symptoms related to male ageing and possible androgen deficiency: the Ageing Males' Symptoms (AMS) scale developed by Claudia Moore et al., and the Androgen Deficiency in Ageing Males (ADAM) questionnaire created by Morley et al [18]. The AMS scale evaluates 17 aspects of male health, divided into three categories: psychological, somatic, and sexual symptoms, providing a broad overview of overall well-being. In contrast, the ADAM questionnaire—often used in a simplified form—places a stronger emphasis on sexual symptoms, with their presence considered central to making a diagnosis [19]. The full version of the ADAM questionnaire includes the following 10 questions:

1. Do you have a decrease in libido or sex drive?
2. Do you lack energy?
3. Have you noticed a decrease in strength and/or endurance?
4. Have you lost height?
5. Have you experienced a decline in your enjoyment of life?
6. Do you feel sad or irritable?
7. Are your erections less strong?
8. Have you noticed a recent decline in your ability to play sports?
9. Do you often fall asleep after dinner?
10. Has your performance at work recently deteriorated?

Initially, these questionnaires were often regarded as standalone diagnostic tools, and

positive results were considered sufficient to qualify a patient for testosterone therapy. The aim of treatment was not necessarily to correct a documented hormonal deficiency, but rather to identify men who might benefit from testosterone administration. In practice—particularly in the United States—testosterone therapy was frequently promoted as a way to delay or prevent ageing, rather than strictly treat a deficiency. Even at the time, it was evident that not all men experience a significant testosterone decline, unlike the uniform estrogen drop seen in postmenopausal women. The *Massachusetts Male Ageing Study (MMAS)* followed a group of men over the long term and found that:

- 21% of men aged 55–59,
- 26% of men aged 60–69, and
- 31% of men aged 70–86

did not meet the diagnostic criteria for low testosterone levels. Another study further demonstrated that these percentages would drop significantly if two essential criteria were assessed separately: the presence of clinical symptoms and testosterone levels below the normal range.

The average age of participants in the study was 47.3 years (± 12.5). Among them, approximately 24% had total testosterone levels below 300 ng/dL, and 11% had free testosterone levels below 5 ng/dL. Reported symptom prevalence included:

- Low libido – 12%
- Erectile dysfunction – 16%
- Osteoporosis or fractures – 1%
- Two or more non-specific symptoms – 20%

While low testosterone levels were linked to the presence of symptoms, many men with low levels were asymptomatic, especially those over the age of 50 (47.6%). The overall crude prevalence of symptomatic androgen deficiency was estimated at 5.6% (95% CI: 3.6–8.6%), with no significant variation across race or ethnicity. The prevalence remained relatively low in men under 70 (3.1–7.0%) but increased sharply to 18.4% among men aged 70 and older [14]. In summary, there is broad consensus that testosterone replacement therapy is clearly indicated when total serum testosterone falls below 8 nmol/L (231 ng/dL) or free testosterone is below 180 pmol/L (52 pg/mL). For men with total testosterone levels between 8 and 12 nmol/L, treatment may be considered if clinical symptoms are present and free testosterone is below 225 pmol/L [20]. A significant challenge for clinicians—particularly in Poland—is the lack of standardized reference ranges across laboratories. Each lab uses its own set of norms, often without a clear scientific basis, and many define the lower limit of normal as less than 300 ng/dL, making it difficult to compare results with data from published studies. Moreover, large-scale studies such as the Massachusetts Male Ageing Study (MMAS) and the European Male Ageing Study (EMAS) also applied different lower cut-off values, adding further inconsistency in defining testosterone deficiency.

ADVANTAGES OF MALE MENOPAUSE:

- Emotional maturity and stability: Decreased aggression and increased self-awareness.
- Perspective on life: Opportunities for reflection, growth, and deeper meaning.
- Improved relationships: More emotionally fulfilling interactions with others.
- Mental and emotional health: Increased focus on mindfulness, stress reduction, and overall well-being.
- Financial and professional flexibility: Greater stability and confidence in career and finances.
- Health focus: More attention to physical health, fitness, and preventive care.
- Freedom from reproductive pressures: Liberation from societal pressures around fatherhood and masculinity.

DISADVANTAGES OF MALE MENOPAUSE:

- Reduced energy levels and increased fatigue.
- Decreased libido and sexual dysfunction (e.g., erectile dysfunction).
- Mood swings, irritability, and depression.
- Weight gain, particularly around the abdomen, and increased body fat.

- Decreased bone density, leading to an increased risk of fractures.
- Increased risk of chronic conditions like cardiovascular disease, diabetes, and hypertension.
- Impact on professional life, leading to potential career difficulties or retirement.

Managing the Disadvantages

While these disadvantages can be challenging, many of them can be addressed with proper medical care, lifestyle changes, and support. For instance:

- Testosterone Replacement Therapy (TRT) may help alleviate many of the physical symptoms (e.g., fatigue, low libido, muscle loss).
- Exercise (particularly strength training) and a healthy diet can help mitigate muscle loss, promote fat loss, and improve overall physical health.
- Mental health support, including therapy or counseling, can help address emotional challenges like depression and anxiety.
- Sleep hygiene practices and stress management techniques can help with sleep disturbances and improve overall well-being.

SYMPTOMS OF MALE MENOPAUSE:

1. Physical Symptoms

Fatigue and Low Energy

- Description: Many men experience persistent tiredness or a general lack of energy.
- Causes: This can result from hormonal changes, poor sleep, or underlying health conditions.
- Management: Improving sleep hygiene, regular physical activity, and a balanced diet can help alleviate fatigue.

Decreased Muscle Mass and Strength

- Description: A noticeable reduction in muscle tone and strength.
- Causes: Declining testosterone levels contribute to muscle loss.
- Management: Engaging in resistance training and ensuring adequate protein intake can help maintain muscle mass.

Increased Body Fat

- Description: Particularly around the abdomen, leading to weight gain.
- Causes: Lower testosterone levels can lead to increased fat accumulation.
- Management: Regular cardiovascular exercise and a healthy diet can aid in fat reduction.

Gynecomastia (Enlarged Breast Tissue)

- Description: Development of enlarged breast tissue in men.
- Causes: Hormonal imbalances, particularly an increase in estrogen relative to testosterone.
- Management: Medical evaluation is necessary; treatments may include hormone therapy or surgical options.

Reduced Bone Density

- Description: Increased risk of osteoporosis and bone fractures.
- Causes: Testosterone plays a role in bone health; its decline can lead to decreased bone density.
- Management: Weight-bearing exercises and calcium and vitamin D supplementation can support bone health.

2. Sexual Symptoms

Reduced Libido

- Description: Decreased interest in sexual activity.
- Causes: Lower testosterone levels are a primary factor.
- Management: Addressing underlying health issues and open communication with a partner can be beneficial.

Erectile Dysfunction

- Description: Difficulty achieving or maintaining an erection.
- Causes: Hormonal changes, cardiovascular issues, and psychological factors.
- Management: Medical treatments, lifestyle changes, and counseling can help manage this condition.

Reduced Morning Erections

- Description: A decrease in spontaneous erections during sleep.
- Causes: Reduced testosterone levels and other health issues.
- Management: Monitoring and addressing underlying causes with a healthcare provider.

3. Emotional and Psychological Symptoms
Mood Swings and Irritability

- Description: Increased feelings of frustration or anger.
- Causes: Hormonal fluctuations and stress.
- Management: Stress management techniques and counseling can be effective.

Depression

- Description: Feelings of sadness or hopelessness.
- Causes: Hormonal changes, life stressors, and other health conditions.
- Management: Therapy and, if necessary, medication can help manage depressive symptoms.

Anxiety

- Description: Increased nervousness or worry.
- Causes: Hormonal imbalances and stress.
- Management: Relaxation techniques, therapy, and lifestyle changes can alleviate anxiety.

Decreased Motivation

- Description: Lack of enthusiasm for activities once enjoyed.
- Causes: Hormonal changes and depression.
- Management: Setting small goals and seeking professional support can help improve motivation.

Difficulty Concentrating

- Description: Problems with focus and memory.
- Causes: Hormonal fluctuations and stress.
- Management: Cognitive exercises and stress reduction techniques can enhance concentration.

4. Sleep Disturbances
Insomnia

- Description: Difficulty falling or staying asleep.
- Causes: Hormonal changes, stress, and lifestyle factors.
- Management: Establishing a regular sleep routine and creating a restful environment can improve sleep quality.

Disturbed Sleep Patterns:

- Description: Waking up frequently during the night.
- Causes: Hormonal imbalances and other health conditions.
- Management: Addressing underlying health issues and practicing good sleep hygiene can be beneficial [21-25].

DIAGNOSIS OF MALE MENOPAUSE:-
1. Medical History & Symptom Review
Doctors assess:

- Low energy/fatigue
- Depression or mood changes
- Low libido
- Erectile dysfunction
- Poor concentration/memory
- Decreased muscle mass
- Sleep disturbances

2. Physical Exam

- Evaluation of body composition
- Examination for testicular atrophy or gynecomastia

3. Laboratory Tests

- Total Testosterone (morning levels preferred; levels < 300 ng/dL often considered low)
- Free Testosterone (if total testosterone is borderline)
- LH & FSH – to rule out primary or secondary hypogonadism
- Prolactin – to check for pituitary disorders
- Thyroid function tests
- PSA (Prostate-Specific Antigen) before considering testosterone therapy

TREATMENT FOR MALE MENOPAUSE:-
1. Lifestyle Modifications for Andropause Treatment
Exercise: Resistance and Aerobic Training

- Aerobic Exercise: Engaging in regular aerobic activities such as running, walking, swimming, or cycling can help boost overall health and testosterone levels. Aerobic exercise has been shown to improve cardiovascular health, reduce fat mass, and improve insulin sensitivity, all of which can help mitigate symptoms of low testosterone.
- Resistance Training: Strength training or resistance exercise (weightlifting,

bodyweight exercises) is particularly beneficial for muscle mass maintenance and testosterone production. Studies suggest that high-intensity resistance training can increase testosterone levels in men, particularly in those who are overweight or obese (Hickson et al., 1981). These exercises stimulate muscle growth, which can counteract the muscle loss typically seen with aging.

Diet: Adequate Protein, Healthy Fats, and Micronutrients

- Protein: Adequate protein intake is essential for maintaining muscle mass and supporting overall hormonal health. Protein helps stimulate muscle protein synthesis and also supports the production of testosterone and other key hormones (Timmons et al., 2016).
- Healthy Fats: Diets rich in healthy fats (omega-3 fatty acids, monounsaturated fats) are associated with improved testosterone levels. Fats are crucial for the production of testosterone since this hormone is synthesized from cholesterol.
- **Micronutrients**:

Zinc: This mineral plays a key role in testosterone synthesis. Zinc deficiency is associated with lower testosterone levels and has been linked to delayed puberty in men (Prasad, 2013). Foods rich in zinc include shellfish, meat, beans, and seeds.

Vitamin D: Research indicates that vitamin D deficiency can lead to lower testosterone levels. Ensuring adequate levels through sunlight exposure or supplementation can be beneficial (Pilz et al., 2011)

Weight Loss

Obesity is one of the key risk factors for low testosterone. Increased body fat, particularly around the abdomen, leads to higher aromatase activity, the enzyme responsible for converting testosterone into estrogen. Weight loss via diet and exercise can significantly improve testosterone levels.

- Studies have shown that even modest weight loss (5-10%) in overweight individuals can restore testosterone levels to normal ranges (Kenny et al., 2007). This is why caloric restriction and exercise are recommended as a primary treatment approach for many men with andropause.

Stress Reduction and Better Sleep

- Stress increases the production of cortisol, which can suppress testosterone production. Effective stress management strategies like meditation, deep breathing exercises, and mindfulness have been shown to lower cortisol levels and boost testosterone.
- Sleep is essential for optimal hormone production. Testosterone levels naturally rise during deep sleep, particularly during rapid eye movement (REM) sleep. Sleep deprivation is associated with a significant reduction in testosterone levels (Leproult & Van Cauter, 2011). Ensuring 7-9 hours of quality sleep each night is crucial for maintaining healthy testosterone levels.

2. Testosterone Replacement Therapy (TRT)

Testosterone Replacement Therapy (TRT) is recommended for men diagnosed with clinically low testosterone levels (below 300 ng/dL) along with significant symptoms of andropause. The goal of TRT is to normalize testosterone levels and alleviate symptoms, which may include fatigue, low libido, erectile dysfunction, and mood disturbances.

Forms of TRT

Gels: Testosterone gels (e.g., AndroGel, Testim) are applied directly to the skin. The testosterone is absorbed through the skin into the bloodstream. Gels are easy to use but can cause skin irritation and can transfer to others through physical contact.

Injections: Testosterone can be injected intramuscularly (e.g., testosterone cypionate, testosterone enanthate). Injections are often administered every 1-2 weeks. Some men prefer this method for its long-lasting effects, though it requires regular doctor visits and can cause fluctuations in testosterone levels (e.g., peaks and troughs).

Administration-on Route	Available formulations	Dose	Advantages	Limitations
Injectables	Testosterone Aqueous Testosterone Enanthate Testosterone Cypionate Testosterone Propionate testosterone undecanoate	25-50mg every 1-2 weeks.250mg every 2-3 weeks. 200mg every 2-3 weeks. 100mg every 2 weeks.1000mg every 10-14 weeks.	Less painful Cost effective Longer effects convenience	Frequent injections Pain at injection site Risk of venous thromboembolism
Oral	Testosterone undecanoate	40-80mg BID/TID with meals.	Ease of oral administration	Variable absorption
Buccal	Buccal, Bio-adhesive, testosterone tablets	30mg controlled release, bio-adhesive tablets BID.	Mimics diurnal variation Quick reversal	Gum-related adverse events in 16%of treated men
Sub-Cutaneous	Surgical Implants	2-6(150-450mg) pellets implanted SC ; every 3-6 months dose and regimen vary with formulation.	Dosing Frequency Improved Compliance	Requires Surgical incision for insertions Pellets may extrude spontaneously.
Topical	Testosterone gel (available in sachets, tubes and pumps), transdermal testosterone patch.	40-5-mg on shoulders, upper arms, abdomen once daily in the morning.1 or 2 patches, designed to nominally deliver 5-10mg T over 24hr applied everyday on non pressure areas	Easy application " Mimics circadian rhythm , easy administration.	Skin irritation at the application site. Cannot use for more than 7 days

Patches: Testosterone patches (e.g., Androderm) are worn on the skin, releasing testosterone continuously. They are applied to the skin at night, but some men find them uncomfortable, and they may cause skin irritation.

Pellets: Implanted under the skin, testosterone pellets (e.g., Testopel) provide a continuous release of testosterone. The implants last 3-6 months and are convenient for men who prefer not to administer daily or weekly doses.

Oral Testosterone: Although not as commonly used, oral testosterone (e.g., Jatenzo) is available but has more limited use due to liver toxicity concerns. This form is typically used when other treatments are not feasible.

Monitoring During TRT

Once treatment begins, it's important to monitor for side effects and ensure efficacy:

- PSA Levels: Increased PSA can indicate prostate enlargement or prostate cancer. Regular PSA testing is recommended, especially in men over 50, before initiating TRT and during treatment.
- Hematocrit: Elevated hematocrit levels can indicate polycythemia, a condition where the blood becomes too thick, which increases the risk of

blood clots, heart attacks, and strokes. Men on TRT need regular hematocrit checks.

- Liver Function Tests: Liver function should be monitored to ensure no adverse effects, particularly with oral forms of testosterone.
- Testosterone Levels: Serum testosterone should be monitored to confirm that it is in the normal range (300–1000 ng/dL). Adjustments to the dosage may be needed based on results.
- Symptoms Improvement: The primary goal of TRT is to improve symptoms such as low libido, energy levels, and muscle mass. Improvements should be assessed regularly.

3. Psychological Counseling

Men experiencing andropause often report mood disorders, including depression, irritability, and anxiety. Psychological counseling can help address emotional and psychological issues related to low testosterone. Cognitive-behavioral therapy (CBT) has been shown to be effective in treating depression and anxiety, while also improving quality of life in men undergoing testosterone therapy (Tannenbaum et al., 2017).

- Sexual Dysfunction: Men with andropause may experience erectile dysfunction or reduced libido. Counseling can help address psychological factors such as performance anxiety or relationship difficulties that might be contributing to sexual issues.

4. Medications for Related Symptoms

- PDE5 Inhibitors: These medications (e.g., Viagra, Cialis) are often prescribed for men with erectile dysfunction. They work by increasing blood flow to the penis and are highly effective in treating ED. PDE5 inhibitors may be used alongside TRT to address sexual dysfunction.
- Antidepressants or Therapy: Men with mood disturbances, depression, or anxiety might benefit from antidepressant medications (e.g., SSRIs like sertraline) or therapy. Psychotherapy (CBT) is effective in addressing mood and anxiety disorders associated with low testosterone [26-32].

CONCLUSION:

Male menopause, or andropause, is a natural part of aging, typically beginning around the age of 40, marked by a gradual decline in testosterone levels. Unlike female menopause, which involves a more dramatic and sudden drop in hormones, andropause is characterized by a gradual decline, often leading to a wide range of physical, emotional, and psychological symptoms. These symptoms may include fatigue, reduced libido, muscle loss, mood swings, and erectile dysfunction, which can significantly affect a man's quality of life. While there are notable disadvantages, such as decreased energy, mental clarity, and sexual function, there are also potential benefits of male menopause, including emotional maturity, increased life perspective, and freedom from reproductive pressures. Furthermore, lifestyle changes, including exercise, diet, stress management, and, when appropriate, testosterone replacement therapy (TRT), can help mitigate many of the negative effects associated with andropause. Understanding andropause as a normal, natural process allows men to approach this phase with greater awareness and preparedness. Healthcare interventions, such as TRT, along with emotional support and physical wellness strategies, can help men manage symptoms and continue to lead fulfilling, healthy lives well into their later years. It is important for men experiencing symptoms to consult with a healthcare professional to tailor an approach that best suits their individual needs and goals [33-36].

REFERENCES:

1. CG H. The male climacteric: its symptomatology, diagnosis and treatment. JAMA. 1994;126:1441-3
2. Heinemann LA, Thiel C, Assmann A, et al. Sex differences in 'climacteric symptoms'with increasing age? A hypothesis-generating analysis of

cross-sectional population surveys. Aging Male. 2000;3:124-31.
3. Heinemann K, Saad F. Sweating attacks: key symptom in menopausal transition only for women. Eur Urol 2003;44:583-7
4. Harrison J. 'Talking about my generation': a state-of-the-art review of health information for men in the andropause. Health Info Libr J. 2011;28:161-70.
5. Matsumoto AM. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci. 2002;57:M76-99.
6. Travison TG, Araujo AB, Kupelian V, et al. The relative contributions of aging, health and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab. 2007;92:549-55.
7. Humeniuk E, Bojar I, Owoc A, et al. Psychosocial conditioning of depressive disorders in post-menopausal women. Ann Agric Environ Med 2011; 18: 441-445.
8. Heller CG, Myers GB. The male climacteric, its symptomatology, diagno-sis and treatment. JAMA 1944; 126: 472-477.
9. Heinemann K, Saad F. Sweating attacks: key symptom in menopausal transistion only for women? Eur Urol 2003; 44: 583-587.
10. Heinemann LAJ, Thiel C, Assman A, et al. Sex differences of "climacteric symptoms" with inceraing age? A pooled analysis of cross-sectional population-based surveys. Aging Male 2000; 3: 124-131.
11. Harrison J. 'Talking about my generation': a state-of-the-art review of health information for men in the andropause. Health Info Libr J 2011; 28: 161-170.
12. Huhtaniemi I. Late-onset hypogonadism: current concepts and contro-versies of pathogenesis, diagnosis and treatment. Asian J Androl 2014;16: 192-202.
13. Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl 2005; 28: 125-127.
14. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007; 92: 4241-4247.
15. Huhtaniemi I, Mäkinen JI, Perheentupa A, Raitakari OT. Late-onset hypo- gonadism in men. Experience from the Turku Male Ageing Study (TuMAS). Hormones (Athens) 2008; 7: 36-45.
16. Belchetz PE, Barth JH, Kaufman JM. Biochemical endocrinology of the hypogonadal male. Ann Clin Biochem 2010; 47: 503-515.
17. Wu CY, Yu TJ, Chen MJ. Age related testosterone level changes and male andropause syndrome. Chang Gung Med J 2000; 23: 348-353.
18. Moore C, Huebler D, Zimmermann T, et al. The Aging Males Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency.Eur Urol 2004; 46: 80-87.
19. Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49:1239-1242.
20. Wang C, Nieschlag E, Swerdloff R, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009; 12: 5-12.
21. Healthline. (2023, May 30). *What is male menopause?* Retrieved April 27, 2025, from https://www.healthline.com/health/menopause/male
22. Mayo Clinic Staff. (n.d.). *Male menopause: Myth or reality?* Mayo Clinic. Retrieved April 27, 2025, from https://www.mayoclinic.org/healthy-lifestyle/mens-health/in-depth/male-menopause/art-20048056

23. Health. (2023). *Signs and symptoms of low testosterone.* Retrieved April 27, 2025, from https://www.health.com/low-testosterone-symptoms-7548137
24. Nieschlag, E., & Behre, H. M. (2012). *Testosterone: Action, deficiency, substitution* (4th ed.). Cambridge University Press.
25. Morales, A., Lunenfeld, B., & Skakkebaek, N. E. (2002). Androgen deficiency in the aging male: Guidelines for diagnosis and treatment. *International Journal of Impotence Research, 14*(4), 193–199. https://doi.org/10.1038/sj.ijir.3900854
26. Hickson, R. C., et al. (1981). Effects of heavy resistance training on serum testosterone and cortisol concentrations in men. *Journal of Applied Physiology*, 51(1), 127-132.
27. Timmons, J. A., et al. (2016). Endurance exercise training increases total and free testosterone concentrations in middle-aged men. *Journal of Endocrinology*, 228(2), 167-175.
28. Prasad, A. S. (2013). Zinc in human health: Effect of zinc on immune cells. *Molecular Medicine*, 19(1), 1-9.
29. Pilz, S., et al. (2011). Effects of vitamin D on testosterone levels in men. *Hormone and Metabolic Research*, 43(3), 222-225.
30. Leproult, R., & Van Cauter, E. (2011). Role of sleep and sleep loss in hormonal release and metabolism. *Current Diabetes Reports*, 11(1), 1-7.
31. Kenny, A. M., et al. (2007). Effect of weight loss and exercise on testosterone levels in older obese men: A randomized controlled trial. *The Journal of Clinical Endocrinology & Metabolism*, 92(11), 4135-4142.
32. Tannenbaum, C., et al. (2017). The role of testosterone in mood and cognition in men with low testosterone: A systematic review. *The Journal of Clinical Psychiatry*, 78(1), 28-40.
33. Zarrouf, F. A., Artz, S., Griffith, J., & Coyle, C. M. (2009). Testosterone and depression: Systematic review and meta-analysis. *Journal of Psychiatric Practice*, 15(4), 289-305. https://doi.org/10.1097/01.pra.0000353190.01953.f1
34. Corona, G., Rastrelli, G., & Maggi, M. (2016). Testosterone and the metabolic syndrome. *Journal of Sexual Medicine*, 13(9), 1413-1423. https://doi.org/10.1016/j.jsxm.2016.06.358
35. Finkle, W. D., & Greenland, S. (2014). Testosterone therapy and cardiovascular risk. *The Journal of the American Medical Association (JAMA)*, 312(16), 1657-1668. https://doi.org/10.1001/jama.2014.9739
36. Bhasin, S., & Cunningham, G. R. (2010). Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. *The Journal of Clinical Endocrinology & Metabolism*, 95(6), 2536-2559. https://doi.org/10.1210/jc.2010-0404